Navneet Majhail, Physician-in-Chief of Blood Cancers at Sarah Cannon Cancer Network, shared a post on LinkedIn:
“Quoting Dr Haydar Frangoul from our Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, whose leadership has contributed to the extension of FDA label for Exa-cel to children 5-11 years of age:
‘For many patients with sickle cell disease and beta thalassemia, the burden of disease begins early in life. These findings reinforce the promise of gene-editing therapy and underscore the importance of continuing rigorous clinical research to evaluate new treatment options for children and individuals affected by these serious blood disorders.'”
Other articles featuring Navneet Majhail on OncoDaily.